SG11201901998WA - Solvate form of (r)-2-amino-3-phenylpropyl carbamate - Google Patents

Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Info

Publication number
SG11201901998WA
SG11201901998WA SG11201901998WA SG11201901998WA SG11201901998WA SG 11201901998W A SG11201901998W A SG 11201901998WA SG 11201901998W A SG11201901998W A SG 11201901998WA SG 11201901998W A SG11201901998W A SG 11201901998WA SG 11201901998W A SG11201901998W A SG 11201901998WA
Authority
SG
Singapore
Prior art keywords
international
pct
amino
solvate form
apc
Prior art date
Application number
SG11201901998WA
Other languages
English (en)
Inventor
Jennifer Leigh Nelson
Fionn Hurley
Original Assignee
Jazz Pharmaceuticals International Iii Ltd
Sk Biopharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61562003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201901998W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals International Iii Ltd, Sk Biopharmaceuticals Co filed Critical Jazz Pharmaceuticals International Iii Ltd
Publication of SG11201901998WA publication Critical patent/SG11201901998WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201901998WA 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate SG11201901998WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662383822P 2016-09-06 2016-09-06
PCT/US2017/050233 WO2018048871A1 (en) 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Publications (1)

Publication Number Publication Date
SG11201901998WA true SG11201901998WA (en) 2019-04-29

Family

ID=61562003

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901998WA SG11201901998WA (en) 2016-09-06 2017-09-06 Solvate form of (r)-2-amino-3-phenylpropyl carbamate

Country Status (12)

Country Link
US (3) US10829443B2 (ko)
EP (2) EP4364794A2 (ko)
JP (2) JP7219213B2 (ko)
KR (1) KR102513800B1 (ko)
CN (1) CN109996540A (ko)
CA (1) CA3036071A1 (ko)
DK (1) DK3509582T3 (ko)
FI (1) FI3509582T3 (ko)
MY (1) MY197630A (ko)
PH (1) PH12019500493A1 (ko)
SG (1) SG11201901998WA (ko)
WO (1) WO2018048871A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
KR102513800B1 (ko) * 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
WO2020035769A1 (en) 2018-08-14 2020-02-20 Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
WO2021001457A1 (en) 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
IT202000013855A1 (it) 2020-06-10 2021-12-10 Flamma Spa Un processo per la purificazione del (r)-2-ammino-3-fenilpropil carbammato
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100197892B1 (ko) * 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
CA2355293C (en) 1998-12-23 2005-08-16 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
RU2202607C2 (ru) * 2000-03-03 2003-04-20 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" Штамм бактерий methylophilus methylotrophus - продуцент l-фенилаланина (варианты), способ получения l-фенилаланина
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
MX2007005172A (es) 2004-10-28 2007-06-22 Sk Corp Terapia adjunta para la depresion.
US8440715B2 (en) 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
ATE459393T1 (de) 2005-06-22 2010-03-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
AU2010270971B2 (en) 2009-06-22 2015-08-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
CA2779442A1 (en) 2009-11-06 2011-05-12 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
HUE060060T2 (hu) 2013-03-13 2023-01-28 Jazz Pharmaceuticals Ireland Ltd Kataplexia kezelése
US20150018414A1 (en) 2013-07-12 2015-01-15 Jazz Pharmaceuticals International lll Limited Promotion of Smoking Cessation
US9226910B2 (en) * 2013-07-18 2016-01-05 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
KR20180133244A (ko) 2016-02-16 2018-12-13 더 유니버서티 어브 퀸슬랜드 설포닐유레아 및 관련 화합물 및 이의 용도
KR102513800B1 (ko) * 2016-09-06 2023-03-24 에스케이바이오팜 주식회사 (r)-2-아미노-3-페닐프로필 카바메이트의 용매화물 폼
KR101950254B1 (ko) 2016-09-21 2019-02-20 유상신 차량탑승자의 부재를 감지하는 지능형 카시트

Also Published As

Publication number Publication date
EP3509582A1 (en) 2019-07-17
PH12019500493A1 (en) 2019-05-27
FI3509582T3 (fi) 2024-02-08
US20210053912A1 (en) 2021-02-25
EP3509582B1 (en) 2023-12-20
DK3509582T3 (en) 2024-02-12
CN109996540A (zh) 2019-07-09
WO2018048871A1 (en) 2018-03-15
US11560354B2 (en) 2023-01-24
US20190194126A1 (en) 2019-06-27
JP7219213B2 (ja) 2023-02-07
JP2022003062A (ja) 2022-01-11
EP4364794A2 (en) 2024-05-08
JP2019535643A (ja) 2019-12-12
MY197630A (en) 2023-06-29
EP3509582A4 (en) 2020-05-13
US10829443B2 (en) 2020-11-10
CA3036071A1 (en) 2018-03-15
US20230183172A1 (en) 2023-06-15
KR20190065311A (ko) 2019-06-11
KR102513800B1 (ko) 2023-03-24

Similar Documents

Publication Publication Date Title
SG11201901998WA (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
SG11201903487SA (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
SG11201804363UA (en) Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201808582RA (en) Pyrrolotriazine compounds as tam inhibitors
SG11201811396XA (en) Extreme ultraviolet mask blank with multilayer absorber and method of manufacture
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201803933PA (en) Optical metrology of lithographic processes using asymmetric sub-resolution features to enhance measurement
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201805054QA (en) Apparatus for growing vegetables, mushrooms, ornamental plants and the like
SG11201907544VA (en) Jak inhibitors containing a 4-membered heterocyclic amide
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201903076QA (en) Carbamoyl phenylalaninol compounds and uses therof
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805001UA (en) Method of treating influenza a
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11201804774YA (en) Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
SG11201909807TA (en) Methods of manufacturing of niraparib